統合的マルチオミクスは,メラノーマの薬物反応ネットワークとARID1A依存の耐性メカニズムを定義します
Charlie George Barker1,2, Sumana Sharma1,3, Ana Mafalda Santos3
1European Molecular Biology Laboratory, European Bioinformatics Institute (EMBL-EBI), Wellcome Genome Campus, Hinxton, Cambridgeshire, CB10 1SD, UK.
Molecular systems biology
|February 18, 2026
まとめ
メラノーマにおけるARID1A喪失は,細胞シグナル伝達と免疫回避経路を変更することによって,BRAF/MAPK阻害剤に対する耐性を促進する. PRKD1,JUN,NCK1をターゲットにすることで,この抵抗を克服することができます.
科学分野:
- 腫瘍学 腫瘍学
- 分子生物学は分子生物学である.
- システム生物学 システム生物学
背景:
- BRAF/MAPK阻害剤は,メラノーマ治療に不可欠ですが,耐性に直面しています.
- ARID1Aの変異は,メラノーマにおいて一般的であり,耐性および免疫回避と関連しています.
- 早期の信号応答を理解することは,治療抵抗を克服する鍵です.
研究 の 目的:
- ARID1A-ノックアウトメラノーマ細胞におけるBRAF/MAPK阻害剤耐性の分子メカニズムを調査する.
- 治療回避に関与する重要なシグナル伝達ノードと経路を特定する.
- 抵抗を克服するための潜在的な治療標的を探求する.
主な方法:
- BRAFV600E敏感のメラノーマ細胞系とそのARID1Aノックアウト派生体の比較分析.
- マルチオミクスデータセット (トランスクリプトミクス,プロテオミクスなど) の統合 システム生物学のアプローチを使用しています.
- 信号経路の活性化,受容体チロシンキナーゼ (RTK) の活性,および免疫関連の遺伝子発現の分析.
主要な成果:
- ARID1A-ノックアウト細胞は,転写の再配線を示し,治療後のMAPK1/3とJNKの活動を維持します.
- 抑制されたPRKD1活性化,増加したJUN活性,およびPKCダイナミクスの障害がARID1A-KO細胞で観察されました.
- RTK (EGFR, ROS1) とエフリン受容体の活性が上昇し,HLA関連のタンパク質発現が低下し,細胞外マトリックス成分が強化されたことが確認されました.
- PRKD1,JUN,NCK1は,抵抗を誘発する重要なノードとして特定されました.
結論:
- ARID1Aの喪失は,複雑なシグナル伝達の変化を通じて,BRAF/MAPK阻害剤に対する耐性を授与する.
- ARID1A-ノックアウトは免疫回避メカニズムに影響を与え,免疫療法の有効性に影響を与える可能性があります.
- PRKD1,JUN,NCK1は,メラノーマの治療抵抗性を克服するための有望な治療目標です.
関連する概念動画
Treatment Resistant Cancers
3.8K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.8K
Adaptive Mechanisms in Cancer Cells
7.2K
Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
7.2K
Interactions Between Signaling Pathways
7.4K
Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
7.4K
mTOR Signaling and Cancer Progression
4.9K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
4.9K
Combination Therapies and Personalized Medicine
6.2K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
6.2K


